Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups.
BACKGROUND
Concerns about the hepatitis C virus (HCV) are due to the high risk of chronic liver disease and poor treatment efficacy. Synthesizing evidence from multiple data sources is becoming widely used to estimate HCV-infection prevalence. This paper aims to estimate the prevalence of HCV infection, and the hepatic and extrahepatic sequelae in at-risk groups, using routinely collected data in the Lazio region, Italy.


METHODS
HCV laboratory surveillance and dialysis, hospital discharge, and drug-user registers were used as information sources to identify at-risk groups and to estimate HCV prevalence and sequelae.Full name and birth date were used as linkage keys for the various health registries. Prevalence was estimated as the percentage of cases within the general population and the at-risk groups, with 95% confidence intervals (95% CI) from 1997 to 2001. The risk of sequelae was estimated through a follow-up of hospital discharges up to December 31, 2004 and calculated as the prevalence ratio in HCV-positive and HCV-negative people, within each at-risk group, with 95% CI.


RESULTS
There were 65,127 HCV-infected people in the study period; the prevalence was 1.24% (95%CI = 1.23%-1.25%) in the whole population, higher in males and older adults. Drug users (35.1%; 95%CI = 34.6-35.7) and dialysis patients (21.1%; 95%CI = 20.2%-22.0%) showed the highest values. Medical procedures with little exposure to blood resulted in higher estimates, ranging between 1.3% and 3.4%, which was not conclusively attributable to the surgical procedures. Cirrhosis, hepatocellular carcinoma and encephalopathy were the most frequent hepatic sequelae; cryoglobulinaemia and non-Hodgkin's lymphoma were the most frequent extrahepatic sequelae.


CONCLUSIONS
Synthesising data from multiple routine sources improved estimates of HCV prevalence and sequelae in dialysis patients and drug users, although prevalence validity should be assessed in survey and sequelae need a well-defined longitudinal approach.
Faustini
Annunziata
A
Department of Epidemiology, Regional Health System - Lazio Region, Via S, Costanza 53, 00198, Rome, Italy. faustini@asplazio.it
Colais
Paola
P
Fabrizi
Emanuele
E
Bargagli
Anna Maria
AM
Davoli
Marina
M
Di Lallo
Domenico
D
Di Napoli
Anteo
A
Pezzotti
Patrizio
P
Sorge
Chiara
C
Grillo
Rita
R
Maresca
Carla
C
Recchia
Olga
O
Perucci
Carlo A
CA
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006526:Hepatitis C / Q000150:complications* / Q000453:epidemiology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007558:Italy / Q000453:epidemiology; D008103:Liver Cirrhosis / Q000453:epidemiology; D008113:Liver Neoplasms / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000453:epidemiology; D015995:Prevalence; D006435:Renal Dialysis / Q000009:adverse effects; D012737:Sex Factors; D019966:Substance-Related Disorders / Q000150:complications; D055815:Young Adult
J Viral Hepat. 2008 Jul;15(7):538-50
18397223
Lancet. 1998 Jan 31;351(9099):351-5
9652633
J Clin Virol. 2009 Mar;44(3):200-6
19195927
Gut. 1999 Jun;44(6):874-80
10323892
Am J Kidney Dis. 2001 May;37(5):1004-10
11325683
Rev Soc Bras Med Trop. 2009 May-Jun;42(3):239-44
19684968
Int J Epidemiol. 2007 Aug;36(4):731-7
17693458
JAMA. 1996 Nov 20;276(19):1563-7
8918853
Am J Gastroenterol. 2001 Nov;96(11):3138-41
11721761
Blood. 2004 Mar 1;103(5):1618-24
14576071
Blood. 2003 Aug 1;102(3):996-9
12714514
J Hepatol. 2001 Aug;35(2):284-9
11580153
Am J Kidney Dis. 2006 Oct;48(4):629-37
16997059
Minerva Urol Nefrol. 2005 Sep;57(3):175-97
15986016
N Engl J Med. 2001 Jul 5;345(1):41-52
11439948
J Med Virol. 2005 Dec;77(4):509-18
16254983
NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46
14768714
N Engl J Med. 1997 Jul 24;337(4):237-40
9227929
J Hepatol. 2008 Jan;48(1):148-62
18022726
Cent Eur J Public Health. 2008 Sep;16(3):106-10
18935772
Clin Nephrol. 2009 Apr;71(4):423-9
19356375
BMC Public Health. 2009 Jan 22;9:34
19161623
J Med Virol. 2009 May;81(5):836-43
19319981
Blood. 2002 Jun 15;99(12):4588-91
12036892
Lancet. 2003 Dec 20;362(9401):2095-100
14697814
BMJ. 1998 Aug 15;317(7156):433-7
9703523
Infect Control Hosp Epidemiol. 2005 Sep;26(9):762-7
16209382
World J Gastroenterol. 2009 Apr 7;15(13):1537-47
19340895
Ann Intern Med. 2006 May 16;144(10):705-14
16702586
BMJ. 2002 Feb 23;324(7335):450-3
11859045
J Pediatr. 2003 Jul;143(1):54-9
12915824
Lancet Infect Dis. 2005 Sep;5(9):558-67
16122679
Biostatistics. 2008 Oct;9(4):715-34
18349037
J Rheumatol. 1999 Feb;26(2):370-2
9972971
World J Gastroenterol. 2007 May 7;13(17):2436-41
17552026
Int J Epidemiol. 2003 Oct;32(5):717-24
14559738
World J Gastroenterol. 2007 May 7;13(17):2467-78
17552031
N Engl J Med. 1999 Aug 19;341(8):556-62
10451460